{"url_path":"/sec/bixt/8-k/2026-08-11/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1445815/0001493152-26-036977-index.html","accession_number":"0001493152-26-036977","cik":"0001445815","ticker":"BIXT","issuer_name":"BIOXYTRAN, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1445815/0001493152-26-036977-index.html","primary_entity_key":"0001445815","primary_entity_name":"BIOXYTRAN, INC"},"word_count":48,"has_tables":true,"body_markdown":"**Item\n8.01. Other Events**\n\n \n\nOn\nAugust 11, 2026, the Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title:\n\n \n\n**Bioxytran\nReports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID,\na Novel Galectin Antagonist Designed with Artificial Intelligence**"}